Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023
03 Jan 2023
Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023
Company to be in San Francisco January 8-12, 2023, during 41st Annual J.P. Morgan Health Care Conference
WOBURN, Mass. and HAIFA, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the Company will be presenting at the Biotech Showcase on Tuesday, January 10, 2023, at the Hilton San Francisco Union Square Hotel in San Francisco, CA.
Time: 9:45 AM PST
Track: Franciscan C (Ballroom Level)
Biotech Showcase is an investor conference featuring insights from top investors and biopharma executives.
Interested parties can register to attend the event here:
https://informaconnect.com/biotech-showcase/registration-options/
Additionally, CEO Natalie Yivgi-Ohana and CBO Shai Melcer will be in San Francisco from January 8-12, 2023, during the 41st Annual J.P. Morgan Health Care Conference and will be available for meetings with investors.
Individuals interested in meeting with CEO Natalie Yivgi-Ohana and CBO Shai Melcer can contact shai.melcer@minoviatx.com
About Minovia
Minovia Therapeutics is a clinical-stage global biotechnology company committed to the discovery and development of novel approaches to treating diseases caused by mitochondrial dysfunction. Minovia’s Mitochondrial Augmentation Technology (MAT) platform is designed to extend and enhance human lives by restoring mitochondrial function using autologous stem cells enriched with healthy, functional mitochondria. This unique approach capitalizes on the natural ability of mitochondria to transfer between cells. The company’s initial clinical focus is on primary mitochondrial diseases, such as Pearson syndrome, a fatal pediatric disease, and hematological disorders that include mitochondrial dysfunction.
Findings on safety and efficacy of MAT, both pre-clinical and clinical, may be found in these publications:
https://www.nature.com/articles/s41536-021-00167-7
https://www.science.org/doi/10.1126/scitranslmed.abo3724
Minovia was founded by leading researchers in mitochondrial biology and is headquartered in Haifa, Israel, with operations in Massachusetts.
For more information, visit http://minoviatx.com/.
Contact Information
Shai Melcer, CBO
3 HaSadna st., Tirat Carmel
Israel
Shai.melcer@minoviatx.com
+972-747033354
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.